← All drugs Report issue

amg-780

mAbexperimental

Clinical trial activity

1 trials · 1 clinical orgs · 0 marketing orgs

Phase 1

1

Phase 2

0

Phase 3

0

Phase 4

0

Earliest trial started Jun 1, 2010 (NCT01137552)

Timeline

2010s

Jan 1, 2010
Earliest Phase 1 Sponsor(trial)

Indications

Studied for

Neoplasms · Phase 1

Mechanism of action

Angiopoietin-2INHIBITOR
ANGPT2 inhibitor
- Angiopoietin-2 (ANGPT2) ↗
Angiopoietin-1INHIBITOR
ANGPT1 inhibitor
- Angiopoietin-1 (ANGPT1) ↗
Tyrosine-protein kinase TIE-2INHIBITOR
TEK inhibitor
- Angiopoietin-1 receptor (TEK) ↗

Chemistry & pharmacology

Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Multi-specific: No

Oral

No

Parenteral

No

Topical

No

Sources

ChEMBLCHEMBL2109586 ↗

Also known as

amg 780
amg-780

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT01137552	Phase 1	Jun 1, 2010	Amgen

Showing 1 of 1 trials

Page 1 / 1

Organizations

Research & Development (1)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Amgen	For profit	1	1	1	2010

1 organizations

Page 1 / 1